The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics

Clinical Pharmacology and Therapeutics

Volumn 59, Issue 4, 1996, Pages 429-435

  Harris, Robert Z ^a,b   Tsunoda, Shirley M ^a   Mroczkowski, Patrick ^a   Wong, Harrison ^a,c   Benet, Leslie Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c AvMax Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; ENZYME; ERYTHROMYCIN; ESTROGEN; GESTAGEN; PREDNISOLONE; PREDNISOLONE SODIUM PHOSPHATE;

ADULT; ARTICLE; BREATH ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HORMONE SUBSTITUTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MENOPAUSE; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL;

ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL AVAILABILITY; BREATH TESTS; CYTOCHROME P-450 ENZYME SYSTEM; ERYTHROMYCIN; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HALF-LIFE; HUMANS; MENOPAUSE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PREDNISOLONE; PROGESTINS;

EID: 0029880041     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90112-5     Document Type: Article

References (36)

1. Gustavson LE, Benet LZ. Menopause: pharmacodynamics and pharmacokinetics. Exp Gerontol 1994;29: 437-44.
2. Lemmens HJM, Burm AGL, Hennis PJ, Gladines MPPR, Bovill JG. Influence of age on the pharmacokinetics of alfentanil. Clin Pharmacokinet 1990;19: 416-22.
3. Rubio A, Cox C. Sex, age and alfentanil pharmacokinetics. Clin Pharmacokinet 1991;21:81-2.
4. Yun CH, Wood AJ, Guengerich FP. Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4. An explanation of the variable elimination clearance. Anesthesiology 1992;77:467-74.
5. Gustavson LE, Legler UF, Benet LZ. Impairment of prednisolone disposition in women taking oral contraceptives or conjugated estrogens. J Clin Endocrinol Metab 1986;62:234-7.
6. Frey FJ, Frey BM, Benet LZ. Liquid-chromatographic measurement of endogenous and exogenous glucocorticoids in plasma. Clin Chem 1979;25:1944-7.
7. Hale VG, Benet LZ. Prednisolone and prednisone exhibit linear extraction in perfused rabbit liver. Drug Metab Dispos 1991;19:87-93.
8. Frey FJ, Frey BM, Greither A, Benet LZ. Prednisolone clearance at steady state in dogs. J Pharmacol Exp Ther 1980;215:287-91.
9. Tozer TN, Gambertoglio JG, Furst DE, Avery DS, Holford NG. Volume shifts and protein binding estimates using equilibrium dialysis: application to prednisolone binding in humans. J Pharm Sci 1983;72:1442-6.
10. Benet LZ, Galeazzi RL. Noncompartmental determination of the steady state volume of distribution. J Pharm Sci 1979;68:1071-4.
11. Turgeon DK, Leichtman AB, Lown KS, et al. P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients. CLIN PHARMACOL THER 1994;56: 253-60.
12. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid inducible liver cytochrome P-450. J Clin Invest 1989;83:688-97.
13. Watkins PB, Turgeon DK, Saenger P, et al. Comparison of urinary 6-β-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. CLIN PHARMACOL THER 1992;52:265-73.
14. Milsap RL, Plaisance KI, Jusko WJ. Prednisolone disposition in obese men. CLIN PHARMACOL THER 1984; 36:824-31.
15. Stuck AE, Frey BM, Frey FJ. Kinetics of prednisolone and endogenous cortisol suppression in the elderly. CLIN PHARMACOL THER 1988;43:354-62.
16. Benet LZ, Zia-Amirhosseini P. Basic principles of pharmacokinetics. Toxicol Pathol 1995;23:115-23.
17. Meffin PJ, Brooks PM, Sallustio BC. Alterations in prednisolone disposition as a result of time of administration, gender and dose. Br J Clin Pharmacol 1984; 17:395-404.
18. Lew KH, Ludwig EA, Milad MA, et al. Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. CLIN PHARMACOL THER 1993;54: 402-14.
19. Kerr BM, Thummel KE, Wurden CJ, et al. Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994;47:1969-79.
20. Kerlan V, Dreano Y, Bercovici JP, Beaune PH, Floch HH, Berthou F. Nature of cytochromes P450 involved in the 2-/4-hydroxylations of estradiol in human liver microsomes. Biochem Pharmacol 1992;44:1745-56.
21. Etienne MC, Milano G, Rene N, et al. Improved bioavailability of a new oral preparation of medroxyprogesterone acetate. J Pharm Sci 1991;80:1130-2.
22. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-84.
23. Holazo AA, Winkler MB, Patel IH. Effects of age, gender and oral contraceptives on intramuscular midazolam pharmacokinetics. J Clin Pharmacol 1988;28: 1040-5.
24. Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 1984; 61:27-36.
25. Garg V, Jusko WJ. Simultaneous analysis of prednisone, prednisolone and their major hydroxylated metabolites in urine by high-performance liquid chromatography. J Chromatogr 1991;567:39-47.
26. Rodchenkov GM, Vedenin AN, Uralets VP, Semenov VA. Characterization of prednisone, prednisolone and their metabolites by gas chromatography - mass spectrometry. J Chromatogr 1991;565:45-51.
27. Waxman DJ, Attisano C, Guengerich FP, Lapenson DP. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6β-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys 1988;263:424-36.
28. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.
29. Lee KH, Shin JG, Chong WS, et al. Time course of the changes in prednisolone pharmacokinetics after administration or discontinuation of rifampin. Eur J Clin Pharmacol 1993;45:287-9.
30. Prichard L, Fabre I, Fabre G, et al. Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990;18:595-606.
31. Prichard L, Fabre I, Daujat M, Domergue J, Joyeux H, Maurel P. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol 1992;41:1047-55.
32. Kinirons MT, O'Shea D, Downing TE, et al. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. CLIN PHARMACOL THER 1993;54:621-9.
33. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23.
34. Krivoruk, Y, Kinirons MT, Wood AJ, Wood M. Metabolism of cytochrome P450 A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test. CLIN PHARMACOL THER 1994;56:608-14.
35. Kolars JC, Awni WM, Merion RM, Watkins PB. First-pass metabolism of cyclosporin by the gut. Lancet 1991;338:1488-90.
36. Strobel HW, Hammond DK, White TB, White JB. Identification and localization of cytochromes P450 in gut. Methods Enzymol 1991;206:648-55.